Carisma Therapeutics logo

Carisma Therapeutics Share Price Today

(NASDAQ: CARM)

Carisma Therapeutics share price is $0.4 & ₹34.79 as on 6 Mar 2025, 2.30 'hrs' IST

$0.4

Market is closed - opens 8 PM, 06 Mar 2025

View live Carisma Therapeutics share price in Dollar and Rupees. Guide to invest in Carisma Therapeutics stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Carisma Therapeutics, along with analyst recommendations, forecasts, and comprehensive financials.

Carisma Therapeutics share price movements

  • Today's Low: $0.40
    Today's High: $0.43

    Day's Volatility :7.34%

  • 52 Weeks Low: $0.38
    52 Weeks High: $2.67

    52 Weeks Volatility :85.77%

Carisma Therapeutics (CARM) Returns

PeriodCarisma Therapeutics IncIndex (Russel 2000)
3 Months
-49.48%
0.0%
6 Months
-59.85%
0.0%
1 Year
-84.61%
0.0%
3 Years
-89.1%
-11.6%

Carisma Therapeutics (CARM) Key Statistics

in dollars & INR

Previous Close
$0.4001
Open
$0.409
Today's High
$0.4317
Today's Low
$0.4
Market Capitalization
$17.1M
Today's Volume
$3.2K
52 Week High
$2.67
52 Week Low
$0.38
Revenue TTM
$20.3M
EBITDA
$-63.4M
Earnings Per Share (EPS)
$-1.49
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-362.79%

How to invest in Carisma Therapeutics Stock (CARM) from India?

It is very easy for Indian residents to invest directly in Carisma Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Carisma Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Carisma Therapeutics or CARM on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Carisma Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Carisma Therapeutics shares which would translate to 2.174 fractional shares of Carisma Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Carisma Therapeutics, in just a few clicks!

Returns in Carisma Therapeutics (CARM) for Indian investors in Rupees

The Carisma Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Carisma Therapeutics investment value today

Current value as on today

₹20,347

Returns

₹79,653

(-79.65%)

Returns from Carisma Therapeutics Stock

₹84,615 (-84.62%)

Dollar Returns

₹4,963 (+4.96%)

Indian investors sentiment towards Carisma Therapeutics (CARM)

-19%

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for Carisma Therapeutics Stock from India on INDmoney has decreased by -19% in the last 30 days, reflecting a downward trend in search activity.

Analyst Recommendation on Carisma Therapeutics

Buy

    91%Buy

    8%Hold

    0%Sell

Based on 12 Wall street analysts offering stock ratings for Carisma Therapeutics(by analysts ranked 0 to 5 stars)

Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
10
10
Hold
1
1
1
Sell
0
0
0

Analyst Forecast on Carisma Therapeutics Stock (CARM)

What analysts predicted

Upside of 1525.0%

Target:

$6.50

Current:

$0.40

Insights on Carisma Therapeutics Stock (Ticker Symbol: CARM)

  • Price Movement

    In the last 3 months, CARM stock has moved down by -49.5%
  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 9.19M → 3.38M (in $), with an average decrease of 63.2% per quarter
  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -11.16M → -12.70M (in $), with an average decrease of 13.8% per quarter
  • CARM vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 62.3% return, outperforming this stock by 146.9%
  • Price to Sales

    ForCARM every $1 of sales, investors are willing to pay $0.8, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $13.8 for every $1 of sales.

CARM Carisma Therapeutics Financials in INR & Dollars

FY20Y/Y Change
Revenue
$11.2M
-
Net Income
$-28.3M
↓ 73.66%
Net Profit Margin
-252.05%
-
FY21Y/Y Change
Revenue
$26.5M
↑ 136.24%
Net Income
$-40.8M
↑ 43.98%
Net Profit Margin
-153.61%
↑ 98.44%
FY22Y/Y Change
Revenue
$9.8M
↓ 62.95%
Net Income
$-61.2M
↑ 50.16%
Net Profit Margin
-622.6%
↓ 468.99%
FY23Y/Y Change
Revenue
$14.9M
↑ 51.71%
Net Income
$-86.9M
↑ 41.9%
Net Profit Margin
-582.34%
↑ 40.26%
Q2 FY23Q/Q Change
Revenue
$3.6M
↑ 9.77%
Net Income
$-19.9M
↓ 19.34%
Net Profit Margin
-558.31%
↑ 201.54%
Q3 FY23Q/Q Change
Revenue
$3.8M
↑ 7.5%
Net Income
$-21.4M
↑ 7.68%
Net Profit Margin
-559.26%
↓ 0.95%
Q4 FY23Q/Q Change
Revenue
$4.3M
↑ 12.07%
Net Income
$-21.0M
↓ 2.08%
Net Profit Margin
-488.65%
↑ 70.61%
Q1 FY24Q/Q Change
Revenue
$3.4M
↓ 20.8%
Net Income
$-19.0M
↓ 9.45%
Net Profit Margin
-558.67%
↓ 70.02%
Q2 FY24Q/Q Change
Revenue
$9.2M
↑ 170.74%
Net Income
$-11.2M
↓ 41.18%
Net Profit Margin
-121.37%
↑ 437.3%
Q3 FY24Q/Q Change
Revenue
$3.4M
↓ 63.19%
Net Income
$-12.7M
↑ 13.8%
Net Profit Margin
-375.24%
↓ 253.87%
FY19Y/Y Change
Profit
$-219.0K
-
FY20Y/Y Change
Profit
$11.2M
↓ 5230.59%
FY21Y/Y Change
Profit
$26.5M
↑ 135.48%
FY22Y/Y Change
Profit
$3.7M
↓ 85.85%
FY23Y/Y Change
Profit
$-59.2M
↓ 1681.36%
Q2 FY23Q/Q Change
Profit
$2.8M
↑ 12.1%
Q3 FY23Q/Q Change
Profit
$3.1M
↑ 10.09%
Q1 FY24Q/Q Change
Profit
$1.7M
-
Q2 FY24Q/Q Change
Profit
$8.9M
↑ 424.77%
Q3 FY24Q/Q Change
Profit
$3.4M
↓ 62.14%
FY20Y/Y Change
Operating Cash Flow
$-27.0M
↓ 28.01%
Investing Cash Flow
$-440.0K
-
Financing Cash Flow
$72.3M
↑ 104.37%
FY21Y/Y Change
Operating Cash Flow
$-37.3M
↑ 38.19%
Investing Cash Flow
$-1.9M
↑ 325.23%
Financing Cash Flow
$16.0M
↓ 77.91%
Q2 FY23Q/Q Change
Operating Cash Flow
$-18.5M
↓ 27.36%
Investing Cash Flow
$35.8M
↑ 0.0%
Financing Cash Flow
$-3.6M
↓ 105.36%

Carisma Therapeutics Technicals Summary

Sell

Neutral

Buy

Carisma Therapeutics is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Carisma Therapeutics (CARM) Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Carisma Therapeutics Inc logo
-13.77%
-59.85%
-84.61%
-89.1%
-89.1%
Regeneron Pharmaceuticals, Inc. logo
1.3%
-41.29%
-30.51%
9.2%
42.38%
Beone Medicines Ltd logo
15.19%
34.31%
61.3%
43.16%
68.1%
Vertex Pharmaceuticals Incorporated logo
3.37%
3.77%
18.06%
106.43%
121.36%
Alnylam Pharmaceuticals, Inc. logo
-11.52%
-3.4%
62.32%
49.04%
120.93%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Carisma Therapeutics Inc logo
NA
NA
NA
-1.2
-3.63
-0.56
NA
-0.27
Regeneron Pharmaceuticals, Inc. logo
17.85
17.85
1.03
43.09
0.16
0.07
0.01
273.57
Beone Medicines Ltd logo
NA
NA
NA
1.43
-0.19
-0.06
NA
31.22
Vertex Pharmaceuticals Incorporated logo
32.84
NA
1.33
18.07
-0.03
0.13
NA
63.87
Alnylam Pharmaceuticals, Inc. logo
NA
NA
-0.49
0.57
-15.01
-0.03
NA
0.52
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Carisma Therapeutics Inc logo
Buy
$17.1M
-89.1%
NA
0.0%
Regeneron Pharmaceuticals, Inc. logo
Buy
$74.9B
42.38%
17.85
31.07%
Beone Medicines Ltd logo
NA
$28.5B
68.1%
NA
-16.92%
Vertex Pharmaceuticals Incorporated logo
Buy
$124.1B
121.36%
32.84
-4.86%
Alnylam Pharmaceuticals, Inc. logo
Buy
$31.5B
120.93%
NA
-12.37%

About Carisma Therapeutics

Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.
Organization
Carisma Therapeutics
Employees
107
CEO
Mr. Steven Kelly
Industry
Miscellaneous

Management People of Carisma Therapeutics

NameTitle
Mr. Steven Kelly
President, CEO & Director
Mr. Michael Klichinsky Ph.D., Pharm.D., PharmD
Co-Founder & Chief Scientific Officer
Dr. Saar Gill M.D., Ph.D.
Co-Founder & Chairman of Scientific Advisory Board
Mr. Tom Wilton
Chief Business Officer
Dr. Eugene P. Kennedy F.A.C.S., M.D.
Chief Medical Officer
Mr. Kenneth Locke
Senior Vice President of Technical Operations

Important FAQs about investing in CARM Stock from India :

What is Carisma Therapeutics share price today?

Carisma Therapeutics share price today stands at $0.40, Open: $0.41 ; Previous Close: $0.40 ; High: $0.43 ; Low: $0.40 ; 52 Week High: $2.67 ; 52 Week Low: $0.38.

The stock opens at $0.41, after a previous close of $0.40. The stock reached a daily high of $0.43 and a low of $0.40, with a 52-week high of $2.67 and a 52-week low of $0.38.

Can Indians buy Carisma Therapeutics shares?

Yes, Indians can invest in the Carisma Therapeutics (CARM) from India.

With INDmoney, you can buy Carisma Therapeutics at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Carisma Therapeutics at zero transaction cost.

How can I buy Carisma Therapeutics shares from India?

It is very easy to buy Carisma Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Carisma Therapeutics (CARM) be purchased?

Yes, you can buy fractional shares of Carisma Therapeutics with INDmoney app.

What are the documents required to start investing in Carisma Therapeutics stocks?

To start investing in Carisma Therapeutics, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Carisma Therapeutics Stock (CARM)?

Today’s highest price of Carisma Therapeutics (CARM) is $0.43.

Today’s lowest price of Carisma Therapeutics (CARM) is $0.40.

What is today's market capitalisation of Carisma Therapeutics?

Today's market capitalisation of Carisma Therapeutics CARM is 17.1M

What is the 52 Week High and Low Range of Carisma Therapeutics Stock (CARM)?

  • 52 Week High

    $2.67

  • 52 Week Low

    $0.38

What are the historical returns of Carisma Therapeutics (CARM)?

  • 1 Month Returns

    -13.77%

  • 3 Months Returns

    -59.85%

  • 1 Year Returns

    -84.61%

  • 5 Years Returns

    -89.1%

Who is the Chief Executive Officer (CEO) of Carisma Therapeutics ?

Mr. Steven Kelly is the current Chief Executive Officer (CEO) of Carisma Therapeutics.